SCHEMBL25105151

SCHEMBL25105151

Cc1cn2cc(NC(=O)c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c4cn(CCF)nc34)cc(F)c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 4/20 0.39
▸ PTPN11 Q06124 1/20 0.38
▸ MAPT P10636 5/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TP53 P04637 2/20 0.38
▸ THRB P10828 1/20 0.37
▸ SCD O00767 1/20 0.36
▸ SCD5 Q86SK9 1/20 0.36
▸ CNR1 P21554 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ GPR35 Q9HC97 1/20 0.35
▸ GPR55 Q9Y2T6 1/20 0.35
▸ USP30 Q70CQ3 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ SMPD3 Q9NY59 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25104208 0.94 BACE1 (0.38) BACE1PTPN11MAPTSMN1; SMN2MEN1
SCHEMBL25103124 0.94 MAPT (0.39) BACE1PTPN11MAPTSMN1; SMN2MEN1
SCHEMBL25105322 0.94 TP53 (0.38) BACE1PTPN11MAPTSMN1; SMN2MEN1
SCHEMBL25104071 0.93 TP53 (0.39) BACE1PTPN11MAPTSMN1; SMN2MEN1
SCHEMBL25105271 0.93 BACE1 (0.37) BACE1PTPN11MAPTSMN1; SMN2MEN1
SCHEMBL25105294 0.92 PTPN11 (0.40) BACE1PTPN11MAPTSMN1; SMN2MEN1
SCHEMBL25104044 0.92 BACE1 (0.38) BACE1PTPN11MAPTSMN1; SMN2MEN1
SCHEMBL25105340 0.92 BACE1 (0.38) BACE1PTPN11MAPTSMN1; SMN2MEN1
SCHEMBL25105082 0.92 MAPT (0.41) BACE1PTPN11MAPTSMN1; SMN2MEN1
SCHEMBL25103717 0.92 TP53 (0.39) BACE1PTPN11MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2025-05-15 — — US disclosed
EP-4395892-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 — — EP disclosed
CN-118302426-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-07-05 — — CN disclosed
WO-2023034812-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 BACE1 668/4885PTPN11 4588/4885MAPT 3414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback